Drugs / LBVD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06947499 | May 2025 → Feb 2028 expected | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2 | LG Chem | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBVD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06947499 ↗ |
| Modality | Vaccine | “LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine” NCT06947499 ↗ |
| Route | Intramuscular | “Intramuscular injection into the anterolateral area of the thigh” NCT06947499 ↗ |